Cargando…

COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?

Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. There...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Beth, Moss, Charlotte, Rigg, Anne, Van Hemelrijck, Mieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105332/
https://www.ncbi.nlm.nih.gov/pubmed/32256706
http://dx.doi.org/10.3332/ecancer.2020.1023
_version_ 1783512378489438208
author Russell, Beth
Moss, Charlotte
Rigg, Anne
Van Hemelrijck, Mieke
author_facet Russell, Beth
Moss, Charlotte
Rigg, Anne
Van Hemelrijck, Mieke
author_sort Russell, Beth
collection PubMed
description Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. Therefore, this review aimed to collate information available in published articles to identify any evidence behind these claims with the aim of advising clinicians on how best to treat patients. This review found no published evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection, however, conflicting evidence from the World Health Organisation surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients.
format Online
Article
Text
id pubmed-7105332
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-71053322020-04-01 COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Russell, Beth Moss, Charlotte Rigg, Anne Van Hemelrijck, Mieke Ecancermedicalscience Short Communication Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. Therefore, this review aimed to collate information available in published articles to identify any evidence behind these claims with the aim of advising clinicians on how best to treat patients. This review found no published evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection, however, conflicting evidence from the World Health Organisation surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients. Cancer Intelligence 2020-03-30 /pmc/articles/PMC7105332/ /pubmed/32256706 http://dx.doi.org/10.3332/ecancer.2020.1023 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Russell, Beth
Moss, Charlotte
Rigg, Anne
Van Hemelrijck, Mieke
COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
title COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
title_full COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
title_fullStr COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
title_full_unstemmed COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
title_short COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
title_sort covid-19 and treatment with nsaids and corticosteroids: should we be limiting their use in the clinical setting?
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105332/
https://www.ncbi.nlm.nih.gov/pubmed/32256706
http://dx.doi.org/10.3332/ecancer.2020.1023
work_keys_str_mv AT russellbeth covid19andtreatmentwithnsaidsandcorticosteroidsshouldwebelimitingtheiruseintheclinicalsetting
AT mosscharlotte covid19andtreatmentwithnsaidsandcorticosteroidsshouldwebelimitingtheiruseintheclinicalsetting
AT rigganne covid19andtreatmentwithnsaidsandcorticosteroidsshouldwebelimitingtheiruseintheclinicalsetting
AT vanhemelrijckmieke covid19andtreatmentwithnsaidsandcorticosteroidsshouldwebelimitingtheiruseintheclinicalsetting